Advertisement
Screener

ORGANOGENESIS HOLDINGS INC. (ORGO) Proceeds from Issuance of Senior Long-term Debt

ORGANOGENESIS HOLDINGS INC. Proceeds from Issuance of Senior Long-term Debt

ORGANOGENESIS HOLDINGS INC. (ORGO) reported Proceeds from Issuance of Senior Long-term Debt of $73.17 million for the 12-month period ending 2021-12-31, per its 10-K filed 2024-02-29.

Discontinued › Cash Flow › Financing Activities

us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt · last filed 2024-02-29

  • ORGANOGENESIS HOLDINGS INC. proceeds from issuance of senior long-term debt for the quarter ending 2021-12-31 was $0.00.
  • ORGANOGENESIS HOLDINGS INC. proceeds from issuance of senior long-term debt for the quarter ending 2020-12-31 was $0.00.
  • ORGANOGENESIS HOLDINGS INC. proceeds from issuance of senior long-term debt for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
  • ORGANOGENESIS HOLDINGS INC. proceeds from issuance of senior long-term debt for the quarter ending 2020-06-30 was $0.00.
  • ORGANOGENESIS HOLDINGS INC. proceeds from issuance of senior long-term debt for fiscal 2021 was $73.17M, a 631.74% increase from fiscal 2020.
  • ORGANOGENESIS HOLDINGS INC. proceeds from issuance of senior long-term debt for fiscal 2020 was $10.00M, a 80.00% decline from fiscal 2019.
  • ORGANOGENESIS HOLDINGS INC. proceeds from issuance of senior long-term debt for fiscal 2019 was $50.00M.
Period endProceeds from Issuance of Senior Long-term Debt 3 monthProceeds from Issuance of Senior Long-term Debt 6 monthProceeds from Issuance of Senior Long-term Debt 9 monthProceeds from Issuance of Senior Long-term Debt 12 month
2021-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29
$73.17M
10-K · filed 2024-02-29
2021-09-30$73.17M
10-Q · filed 2022-11-09
2020-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16
$0.00
derived: sum of 2 quarters · filed 2021-03-16
$0.00
derived: sum of 3 quarters · filed 2021-08-09
$10.00M
10-K · filed 2021-03-16
2020-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09
$0.00
derived: sum of 2 quarters · filed 2021-08-09
$10.00M
10-Q · filed 2020-11-09
$10.00M
derived: sum of 4 quarters · filed 2021-08-09
2020-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09
$10.00M
10-Q · filed 2021-08-09
$10.00M
derived: sum of 3 quarters · filed 2021-08-09
$20.00M
derived: sum of 4 quarters · filed 2021-08-09
2020-03-31$10.00M
10-Q · filed 2021-05-11
$10.00M
derived: sum of 2 quarters · filed 2021-05-11
$20.00M
derived: sum of 3 quarters · filed 2021-05-11
$20.00M
derived: sum of 4 quarters · filed 2021-05-11
2019-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16
$10.00M
derived: sum of 2 quarters · filed 2021-03-16
$10.00M
derived: sum of 3 quarters · filed 2021-03-16
$50.00M
10-K · filed 2021-03-16
2019-09-30$10.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09
$10.00M
derived: sum of 2 quarters · filed 2020-11-09
$50.00M
10-Q · filed 2020-11-09
2019-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10
$40.00M
10-Q · filed 2020-08-10
2019-03-31$40.00M
10-Q · filed 2020-05-11

Similar stocks

Stock NameCountryMarket CapPE Ratio
AN2 Therapeutics, Inc. (ANTX)United States$0.185B-4.84
PepGen Inc. (PEPG)United States$0.186B-1.73
ALX ONCOLOGY HOLDINGS INC (ALXO)United States$0.187B-3.52
Fortress Biotech, Inc. (FBIO)United States$0.188B0.91
Zentalis Pharmaceuticals, Inc. (ZNTL)United States$0.196B-2.48
Tonix Pharmaceuticals Holding Corp. (TNXP)United States$0.166B-1.34
Minerva Neurosciences, Inc. (NERV)United States$0.165B-0.66
ORAMED PHARMACEUTICALS INC. (ORMP)$0.199B1.13
ADC Therapeutics SA (ADCT)$0.163B-1.39
LIFECORE BIOMEDICAL, INC. DE (LFCR)United States$0.163B-8.50